Castle Biosciences Inc (CSTL) - Net Assets
Based on the latest financial reports, Castle Biosciences Inc (CSTL) has net assets worth $470.03 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($561.18 Million) and total liabilities ($91.15 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Castle Biosciences Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $470.03 Million |
| % of Total Assets | 83.76% |
| Annual Growth Rate | N/A |
| 5-Year Change | 14.36% |
| 10-Year Change | N/A |
| Growth Volatility | 143.87 |
Castle Biosciences Inc - Net Assets Trend (2017–2025)
This chart illustrates how Castle Biosciences Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market cap of Castle Biosciences Inc.
Annual Net Assets for Castle Biosciences Inc (2017–2025)
The table below shows the annual net assets of Castle Biosciences Inc from 2017 to 2025. Also explore CSTL net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $470.87 Million | +3.30% |
| 2024-12-31 | $455.83 Million | +16.50% |
| 2023-12-31 | $391.27 Million | -1.97% |
| 2022-12-31 | $399.15 Million | -3.06% |
| 2021-12-31 | $411.74 Million | -0.95% |
| 2020-12-31 | $415.69 Million | +388.40% |
| 2019-12-31 | $85.11 Million | +945.28% |
| 2018-12-31 | $-10.07 Million | +29.44% |
| 2017-12-31 | $-14.27 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Castle Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 17316241600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $30.00K | 0.01% |
| Other Comprehensive Income | $267.00K | 0.06% |
| Other Components | $694.86 Million | 147.57% |
| Total Equity | $470.87 Million | 100.00% |
Castle Biosciences Inc Competitors by Market Cap
The table below lists competitors of Castle Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NB Bancorp, Inc. Common Stock
NASDAQ:NBBK
|
$1.00 Billion |
|
Hartalega Holdings Bhd
KLSE:5168
|
$1.00 Billion |
|
Guangxi Wuzhou Communications Co Ltd
SHG:600368
|
$1.00 Billion |
|
Wah Lee Industrial Corp
TW:3010
|
$1.00 Billion |
|
Shanghai Yaoji Playing Card Co Ltd
SHE:002605
|
$1.00 Billion |
|
Episil-Precision Inc
TW:3016
|
$999.97 Million |
|
Tejas Networks Limited
NSE:TEJASNET
|
$999.16 Million |
|
Shen Ma Industry Co Ltd
SHG:600810
|
$999.01 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Castle Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 455,835,000 to 470,873,000, a change of 15,038,000 (3.3%).
- Net loss of 24,158,000 reduced equity.
- Other comprehensive income increased equity by 37,000.
- Other factors increased equity by 39,159,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-24.16 Million | -5.13% |
| Other Comprehensive Income | $37.00K | +0.01% |
| Other Changes | $39.16 Million | +8.32% |
| Total Change | $- | 3.30% |
Book Value vs Market Value Analysis
This analysis compares Castle Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.19x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-1.46 | $35.50 | x |
| 2018-12-31 | $-0.95 | $35.50 | x |
| 2019-12-31 | $9.83 | $35.50 | x |
| 2020-12-31 | $21.96 | $35.50 | x |
| 2021-12-31 | $16.38 | $35.50 | x |
| 2022-12-31 | $15.32 | $35.50 | x |
| 2023-12-31 | $14.60 | $35.50 | x |
| 2024-12-31 | $15.58 | $35.50 | x |
| 2025-12-31 | $16.24 | $35.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Castle Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.13%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7.02%
- • Asset Turnover: 0.59x
- • Equity Multiplier: 1.23x
- Recent ROE (-5.13%) is below the historical average (-4.06%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | -89.93% | 1.40x | 0.00x | $-10.94 Million |
| 2018 | 0.00% | -27.94% | 1.02x | 0.00x | $-5.36 Million |
| 2019 | 6.20% | 10.17% | 0.43x | 1.41x | $-3.23 Million |
| 2020 | -2.47% | -16.42% | 0.14x | 1.06x | $-51.85 Million |
| 2021 | -7.60% | -33.26% | 0.20x | 1.12x | $-72.47 Million |
| 2022 | -16.82% | -48.99% | 0.31x | 1.12x | $-107.05 Million |
| 2023 | -14.69% | -26.15% | 0.48x | 1.16x | $-96.59 Million |
| 2024 | 4.00% | 5.49% | 0.63x | 1.17x | $-27.34 Million |
| 2025 | -5.13% | -7.02% | 0.59x | 1.23x | $-71.25 Million |
Industry Comparison
This section compares Castle Biosciences Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $281,687,114
- Average return on equity (ROE) among peers: -82.41%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Castle Biosciences Inc (CSTL) | $470.03 Million | 0.00% | 0.19x | $1.00 Billion |
| Agilent Technologies Inc (A) | $2.56 Billion | 27.08% | 1.91x | $42.53 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $1.31 Million | -9.31% | 2.52x | $13.35 Million |
| Applied DNA Sciences Inc (APDN) | $4.87 Million | -204.15% | 1.80x | $3.99 Million |
| Biodesix Inc (BDSX) | $-2.46 Million | 0.00% | 0.00x | $285.72 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.07 Million | 0.00% | 0.00x | $17.63 Million |
| Biocept Inc. (BIOCQ) | $37.48 Million | -7.53% | 0.61x | $262.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $30.47 Million | -271.32% | 5.29x | $4.45 Billion |
| Burning Rock Biotech Ltd (BNR) | $168.49 Million | -77.91% | 1.38x | $102.95 Million |
| CareDx Inc (CDNA) | $19.76 Million | -199.73% | 2.88x | $2.59 Billion |
| Check Cap Ltd (CHEK) | $13.03 Million | -81.27% | 0.18x | $9.42 Million |
About Castle Biosciences Inc
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis fo… Read more